156 related articles for article (PubMed ID: 33482676)
41. Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants.
de Freitas AS; Alvarez-Larrán A
Ann Hematol; 2016 Oct; 95(11):1903-4. PubMed ID: 27518531
[No Abstract] [Full Text] [Related]
42. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.
Naymagon L; Zubizarreta N; Feld J; van Gerwen M; Alsen M; Thibaud S; Kessler A; Venugopal S; Makki I; Qin Q; Dharmapuri S; Jun T; Bhalla S; Berwick S; Christian K; Mascarenhas J; Dembitzer F; Moshier E; Tremblay D
Thromb Res; 2020 Dec; 196():99-105. PubMed ID: 32853982
[TBL] [Abstract][Full Text] [Related]
43. A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19.
Huang Y; Lyu X; Li D; Wang L; Wang Y; Zou W; Wei Y; Wu X
PLoS One; 2020; 15(11):e0242045. PubMed ID: 33166991
[TBL] [Abstract][Full Text] [Related]
44. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
45. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
46. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Brenner B; Hoffman R; Blumenfeld Z; Weiner Z; Younis JS
Thromb Haemost; 2000 May; 83(5):693-7. PubMed ID: 10823264
[TBL] [Abstract][Full Text] [Related]
47. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability.
Tan CW; Low JGH; Wong WH; Chua YY; Goh SL; Ng HJ
Am J Hematol; 2020 Jul; 95(7):E156-E158. PubMed ID: 32267008
[No Abstract] [Full Text] [Related]
48. Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.
Patel R; Czuprynska J; Roberts LN; Vadher B; Rea C; Patel R; Gee E; Saul G; Coles E; Brown A; Byrne R; Speed V; Patel JP; Arya R
Thromb Res; 2021 Jan; 197():192-194. PubMed ID: 33227656
[No Abstract] [Full Text] [Related]
49. COVID-19-associated coagulopathy: a concise review on pathogenesis and clinical implications.
Memar Montazerin S; Najafi H; Shojaei F; Chi G; Goudarzi S; Sharfaei S; Kahe F; Hassanzadeh S
Infez Med; 2021 Mar; 29(1):1-9. PubMed ID: 33664168
[TBL] [Abstract][Full Text] [Related]
50. Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19.
Giannis D; Barish MA; Goldin M; Cohen SL; Kohn N; Gianos E; Chatterjee S; Lesser M; Coppa K; Hirsch JS; McGinn T; Spyropoulos AC;
J Thromb Thrombolysis; 2021 May; 51(4):897-901. PubMed ID: 33665766
[TBL] [Abstract][Full Text] [Related]
51. Dialysis circuit clotting in critically ill patients with COVID-19 infection.
Khoo BZE; Lim RS; See YP; Yeo SC
BMC Nephrol; 2021 Apr; 22(1):141. PubMed ID: 33879086
[TBL] [Abstract][Full Text] [Related]
52. High incidence of stroke in COVID-19 patients.
Chen J; Wu Y; Chen Z; Yi B; Zhang L; Yin C; Feng H
Aging (Albany NY); 2020 Nov; 12(22):22390-22398. PubMed ID: 33221756
[TBL] [Abstract][Full Text] [Related]
53. Contribution value of coagulation abnormalities in COVID-19 prognosis: a bright perspective on the laboratory pattern of patients with coronavirus disease 2019.
Sayyadi M; Khosravi M; Ghaznavi-Rad E
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):518-522. PubMed ID: 33506943
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study.
Anaklı İ; Ergin Özcan P; Polat Ö; Orhun G; Alay GH; Tuna V; Çeliksoy E; Kılıç M; Mercan M; Ali A; Beşışık S; Esen F
Turk J Haematol; 2021 Feb; 38(1):15-21. PubMed ID: 33486940
[TBL] [Abstract][Full Text] [Related]
55. Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation.
Guo Z; Sun L; Li B; Tian R; Zhang X; Zhang Z; Clifford SP; Liu Y; Huang J; Li X
J Cardiothorac Vasc Anesth; 2021 Feb; 35(2):389-397. PubMed ID: 32994131
[TBL] [Abstract][Full Text] [Related]
56. Mean Platelet Volume Predicts Severe COVID-19 Illness.
Lippi G; Henry BM; Favaloro EJ
Semin Thromb Hemost; 2021 Jun; 47(4):456-459. PubMed ID: 33893630
[No Abstract] [Full Text] [Related]
57. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
Li-Saw-Hee FL; Blann AD; Lip GY
Stroke; 2000 Apr; 31(4):828-33. PubMed ID: 10753983
[TBL] [Abstract][Full Text] [Related]
58. Obesity and stroke in the COVID19 era.
Bosque-Varela P; Moscote-Salazar LR; Agrawal A
Clin Neurol Neurosurg; 2020 Sep; 196():105969. PubMed ID: 32492587
[No Abstract] [Full Text] [Related]
59. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.
Haybar H; Maniati M; Saki N; Zayeri ZD
Mol Biol Rep; 2021 Mar; 48(3):2917-2928. PubMed ID: 33837899
[TBL] [Abstract][Full Text] [Related]
60. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
Chan KE; Thadhani RI; Maddux FW
Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
